“Fixer-Upper” Encysive’s Thelin Is Pfizer’s Problem Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma knight rescues Encysive, with its troubled Thelin for pulmonary hypertension, in a deal worth about $200 million.
You may also be interested in...
Another Disappointment For Pfizer; PAH Drug Withdrawn
Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.
Another Disappointment For Pfizer; PAH Drug Withdrawn
Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.
FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced
Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said